Chongqing Nanfang CNC Equipment Co., Ltd. (referred to as "Nanfang CNC" or "the enterprise", stock code: 873512) was founded in 2004 and changed to a joint-stock company in 2019. It is a technological innovation enterprise specializing in the research and development, production, sales and service of in vitro diagnostic (IVD) reagents and instruments.

Nanfang CNC is one of the earliest domestic enterprises engaged in the research and development, production and sales of IVD products. The core value of the enterprise is "people-oriented, technological innovation". It is a national high-tech enterprise, Chongqing Enterprise Technology Center, Chongqing New R&D Institution, Chongqing Specialized Small and Medium-sized Enterprises, and Chongqing Small and Medium-sized Enterprises Little Giant. The company's products have won policy support and awards such as the National Ministry of Science and Technology's Technology Innovation Fund for Science and Technology-based Small and Medium-sized Enterprises and the National Ministry of Science and Technology's Domestic Innovative Medical Devices "Ten Hundred Thousand Project" Demonstration Products. The company has always focused on the field of thrombosis and hemostasis in vitro diagnosis in the field of hemodynamics, formed a core technology cluster covering instruments, reagents and consumables, and has outstanding independent research and development and technological innovation capabilities.

The company is the vice president unit of the Chongqing Medical Device Industry Association. Over the years, it has provided professional products and services to a large number of customers and accumulated rich customer resources. From the 47th China International Medical Devices Expo in 2004 to the 87th Expo today, the company has participated in the exhibition continuously, competing with strong and professional peers, demonstrating the advancement of its products, establishing brand trust, building excellent customer resources and marketing channels for the company's sustainable development, establishing a good brand image, and ensuring the company's steady increase in in vitro diagnostic market share and sustainable profitability.